Krishna G. Prajapati, Nepal
Patan Academy of Health Sciences Paediatric Research UnitPresenter of 1 Presentation
ANTIMICROBIAL SUSCEPTIBILITY PROFILE AND SEROTYPE DISTRIBUTION OF PNEUMOCOCCAL BLOOD CULTURE ISOLATES FROM NEPALESE CHILDREN (ID 672)
- Krishna G. Prajapati, Nepal
- Madhav C. Gautam, Nepal
- Bhishma Pokhrel, Nepal
- Peter J. O'Reilly, United Kingdom
- Meeru Gurung, Nepal
- Merryn Voysey, United Kingdom
- Sanjeev M. Bijukchhe, Nepal
- Sarah Kelly, United Kingdom
- Ganesh Shah, Nepal
- Stephen Thorson, Nepal
- David Murdoch, New Zealand
- Dominic Kelly, United Kingdom
- Maria D. Knoll, United States of America
- Andrew J. Pollard, United Kingdom
- Shrijana Shrestha, Nepal
Author Of 2 Presentations
ANTIMICROBIAL SUSCEPTIBILITY PROFILE AND SEROTYPE DISTRIBUTION OF PNEUMOCOCCAL BLOOD CULTURE ISOLATES FROM NEPALESE CHILDREN (ID 672)
- Krishna G. Prajapati, Nepal
- Madhav C. Gautam, Nepal
- Bhishma Pokhrel, Nepal
- Peter J. O'Reilly, United Kingdom
- Meeru Gurung, Nepal
- Merryn Voysey, United Kingdom
- Sanjeev M. Bijukchhe, Nepal
- Sarah Kelly, United Kingdom
- Ganesh Shah, Nepal
- Stephen Thorson, Nepal
- David Murdoch, New Zealand
- Dominic Kelly, United Kingdom
- Maria D. Knoll, United States of America
- Andrew J. Pollard, United Kingdom
- Shrijana Shrestha, Nepal
THE IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE INTRODUCTION IN NEPAL: A SIX-YEAR PAEDIATRIC SURVEILLANCE STUDY (ID 516)
- Shrijana Shrestha, Nepal
- Meeru Gurung, Nepal
- Stephen Thorson, Nepal
- Bhishma Pokhrel, Nepal
- Bibek Khadka, Nepal
- Pratistha Maskey, Nepal
- Puja Amatya, Nepal
- Madhav C. Gautam, Nepal
- Michael J. Carter, United Kingdom
- Rama Kandasamy, Australia
- Brian Wahl, United States of America
- Sarah Kelly, United Kingdom
- Krishna G. Prajapati, Nepal
- Sonu Shrestha, United Kingdom
- Maria Deloria Knoll, United States of America
- Jason Hinds, United Kingdom
- Ganesh Shah, Nepal
- Dominic Kelly, United Kingdom
- David Murdoch, New Zealand
- Merryn Voysey, United Kingdom
- Andrew J. Pollard, United Kingdom
Abstract
Background
S. pneumoniae is a major cause of bacterial pneumonia and an important cause of invasive bacterial disease (IBD) in children under-five years of age in Nepal. Pneumococcal conjugate vaccine, PCV10, was introduced in 2015 with a 2+1 schedule.
Methods
We assessed the programmatic impact of PCV10 introduction using surveillance for nasopharyngeal (NP) colonisation, pneumonia and IBD. NP swabs from pneumonia inpatients and from healthy children, blood cultures from inpatients with suspected IBD, and chest x-rays from inpatient pneumonia cases were obtained over a 6-year period (2014-2019).
Results
The proportion of pneumonia cases with radiographic endpoint-consolidation (likely bacterial) was 34% lower (95%CI 19-46%) in 2018 compared with the pre-vaccine period (2014-2015). Vaccine serotype (VT) carriage in children under 2-years of age with pneumonia in 2019 was 78% lower (95%CI 30-93%) than in the pre-vaccine period.
Among healthy 6-23 month old children (urban and rural cohorts), VT-carriage declined 74% (95%CI 43-82%) by 2019. An increase in PCV13-additional-serotype carriage was seen in 2018 among rural-children (prevalence-ratio 1.65, 95%CI 1.17-2.32), but not urban-children.
Serotype 1 remains the dominant serotype detected in cases of invasive pneumococcal disease.
Conclusions
A decrease in prevalence of endpoint-consolidation-pneumonia and a decrease in vaccine-serotype circulation have been observed post PCV introduction in Nepal.